The effect of heterologous anti-lymphocyte serum on lymphocytes of thymus and marrow origin.
When CY-treated mice were given sheep red blood cells the serum hemagglutinin titers produced were significantly lower than those found when mice received SRBC but not CY. Titers could be raised to the levels found in the latter group if, in addition to SRBC, the CY-treated mice received 2 x 10(7) normal syngeneic spleen cells or a mixture containing 1.2 x 10(8) normal thymus and 1.2 x 10(8) normal marrow cells. Inocula which contained fewer cells produced correspondingly smaller amounts of antibody. A synergistic interaction between normal thymus and marrow cells was always demonstrable in these experiments. Hemagglutinin titers produced by CY-treated mice given SRBC and 2 x 10(7) normal syngeneic spleen cells were always much higher than those found when the spleen cells were obtained from animals previously given ALS. Titers could be raised to normal levels if the animals in this latter group received additional injections containing mixtures of normal syngeneic thymus and marrow cells. Marrow cells alone were completely ineffective, while inocula which only contained thymus cells were much less effective than mixtures of thymus and marrow cells. These results suggest that immunosuppression by ALS is associated with the inactivation of both thymus and marrow-derived lymphocytes. In other experiments CY-treated mice received SRBC and mixtures of thymus and marrow cells from both untreated and ALS-treated donors. No decrease in the immunological competence of cells located within the thymus of ALS-treated donors was demonstrable in these experiments. Marrow cells were slightly affected but to a markedly lesser degree than were spleen cells of ALS-treated animals. In a final experiment, it was possible to show that the thymus and marrow cells of ALS-treated animals could repair the immunological defects which were present in their own spleen cell populations.
D000818:Animals; D000906:Antibodies / Q000032:analysis; D000917:Antibody Formation; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000494:pharmacology*; D001853:Bone Marrow / Q000276:immunology*; D001854:Bone Marrow Cells; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology; D004912:Erythrocytes / Q000276:immunology; D006386:Hemagglutination Tests; D006736:Horses; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D051379:Mice; D013154:Spleen / Q000276:immunology; D013950:Thymus Gland / Q000276:immunology*
D000906:Antibodies; D000961:Antilymphocyte Serum; D003520:Cyclophosphamide